123results about How to "No side effect" patented technology

A preventive or therapeutic agent for asthma, comprising HGF or its salt as an active ingredient.

A novel method for evaluating an effect of an antimicrobial agent which comprises removing the antimicrobial agent remaining in a biological sample or the like to thereby accurately evaluate the effect of the antimicrobial agent without being affected by the remaining antimicrobial agent. A therapeutic agent for onychomycosis which can be obtained according to the evaluation method of the drug effect.

The present invention relates to a synergistic herbal formulation comprising an active fraction from Azadirachta indica designated as Fraction A and a fraction from Citrullus colocynthis designated as Fraction B, along with a fraction C containing an antioxidant from Cucumis sativus extract; and pharmaceutically accepted a carrier wherein the ratio of the components ranging between about 2 to 5.5% of fraction A; about 0.5 to 2.5% of fraction B; about 0.1–0.4% of extract of Cucumis sativus; and about 82–97% of carrier or additive.

A novel method for evaluating an effect of an antimicrobial agent which comprises removing the antimicrobial agent remaining in a biological sample or the like to thereby accurately evaluate the effect of the antimicrobial agent without being affected by the remaining antimicrobial agent. A therapeutic agent for onychomycosis which can be obtained according to the evaluation method of the drug effect.

The present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives as an effective ingredient. More specifically, the present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives that exhibit superior activity in enhancing metabolic activity, as an effective ingredient.

The present invention relates to hemostatic fabric materials, and to the methods for making and using such materials. In particular, the present invention relates to hemostatic fabric materials made from chemically treated plant materials that are soluble on wound surfaces.

The present invention provides a novel sewing-free hot melt adhesive TPU leather and a preparation method thereof. The hot melt adhesive TPU leather comprises a release paper, a hot melt adhesive film, and a TPU film. The release paper comprises a bottom paper layer, an adhesive layer, a plastic layer, a transition layer, and a release layer; a hot melt adhesive raw material comprises polyester polyol, diisocyanate, polyether polyol, and a plurality of additives; and a TPU raw material comprises polymer polyol, 1,4-cyclohexane-diisocyanate, a chain extender, and a plurality of functional additives. According to the present invention, innovations are conducted on raw material components of the release paper, the hot melt adhesive, and the TPU film, and extrusion shaping is conducted by utilizing the hot melt adhesive with strong plasticity and the TPU thin film; and the prepared sewing-free TPU leather has the technical advantages of firm adhesion, durability, environmentally-friendly materials, no invisible harm to human body, and the like.

This invention has published a composition of medicine and its preparation, which can treat diabetes, hyperlipemia, fatigue and hypoxia. The preparation is as following: 300-1000 part-by-weight of prepared rehmannia root, 150-600 part-by-weight of prepa red dogwood fruit, 100-450 part-by-weight of tree peony bark, 150-600 part-by-weight of chinese yam, 100-450 part-by-weight of indian bread, 100-450 part-by-weight of alisma rhizome, right amount of refined edible vegetable oil are the materials; the tree peony bark is distilled; the residue of the tree peony bark after distillation, the prepared rehmannia root, the chinese yam and the indian bread are decocted to get the mixed liquor; the paeonol mother liquor is added into the mixed liquor to get extracturm I by centrifugation and concentration; the prepared dogwood fruit and the alisma rhizome are extracted in the refluxing alcohol; the extract is concentrated to get extracturm II; the extracturm I and II are mixed and concentrated to the thick paste; the thick paste is dehydrated in the vacuum, smashed and sifting; The refined paeonol is smashed and added into the extracturm powder; the mixed powder is added with right amount of supplementary materials and milled by the colloid mill, sifting screening; the fine powder is made into soft capsule. The invented capsule has the features of bringing into play in a shorter time, better curative effect and lower dose for oral administration, easier to administrate and stable product quality.

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I)(wherein, all the symbols have the same meanings as that of the specification) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and / or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and / or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification.) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and / or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and / or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.

It is to provide a pharmaceutical composition which is different from an existing therapeutic agent of an adult disease, of a biochemical reaction-inhibiting type, and which action mechanism is to improve the basal metabolism, wherein the composition has no side effects, and does not generate drug resistance against adult disease; and a method for preventing / treating an adult disease by using the same. It is to provide a composition for preventing / ameliorating an adult disease such as metabolic syndrome, diabetes, hyperlipidemia, hypertension, impaired liver function, renal failure, adiposity, erectile dysfunction, menopausal disorder, shoulder discomfort, and low back pain, comprising 5-aminolevulinic acid (ALA), its derivative, or salt thereof, preferably comprising ALA, its derivative, or salt thereof, and an iron compound such as sodium ferrous citrate, iron sodium citrate and iron ammonium citrate; a food or food material for preventing / ameliorating an adult disease comprising the composition; and a method for using the composition for preparing an agent for preventing / ameliorating an adult disease.

The present invention discloses a method for remolding bone marrow microenvironment in a subject having an impaired bone marrow microenvironment, which comprises implanting a composition comprising isolated mesenchymal stromal cells (MSCs) into the bone marrow cavity of the subject. The method of the present invention successfully remolds the bone marrow microenvironment, recovers the normal hematopoiesis of bone marrow, inhibits / delays the pathological process of leukemia and significantly prolongs the survival period. In addition, the method according to the present invention can be used for the treatment of hematologic tumors such as leukemia and aplastic anemia (AA), which is safe and effective but has no side effects.

A device for preventing and treating myopia includes a base, a spectacles frame (1), a holder (3) and a lens (2). The holder (3) is mounted on the base; a visual target (4) is placed on the base. The spectacles frame (1) is connected to the holder (3) by adjustable connecting parts (31,32,33,34,35), so the distance between the spectacles frame (1) and the visual target (4) which is placed on the base is adjustable.

This invention is for the compound containing ginsenoside Rg3 as an active ingredient to prevent and treat Hepatitis C virus infection. Specifically, the ginsenoside Rg3 of this invention demonstrated the predominant antiviral activities and apotosis actions in a dose-dependent manner in the Hepatitis C virus infected cells (Huh 7.5.1). Confirmed that it reduces the levels of TNF-α and thioredoxin significantly, and increases phospho-NFκB. It also demonstrated same effectiveness as PegInterferone alpha-2b(PegIFN a-2b, Hepatitis C therapeutics), and has no cytotoxicity to human bodies. Thus, it may be used safely as an active ingredient of medical / pharmaceutical and health food compounds for preventing or treating Hepatitis C.

A method of preparing a Chinese medicine for treatment of diabetes, the medicine including the Radix Rehmanniae Preparata, prepared Asiatic Comelian Cherry fruit, tree peony bark, Common Yam Rhizome, Indian bread, Oriental Waterplain rhizome, and refined edible vegetable oil. The tree peony bark is distilled and its residue, the Radix Rehmanniae Preparata, the Common Yam Rhizome and the Indian bread are decocted, then paeonol mother liquor is added to obtain extractum I by centrifugation and concentration. The prepared Asiatic Comelian Cherry fruit and the Oriental Waterplain rhizome are extracted in the refluxing alcohol and concentrated to obtain extractum II. The two extractum are mixed and concentrated to the thick paste; the thick paste is dried, crushed and sifted. The refined paeonol is crushed and added to the extractum powder. The mixed powder is combined with vegetable oil, milled and sifted. The fine powder is made into soft capsule.

This invention provides albumin preparations with safety and without any risk of side effects, which are free from viruses or contaminating proteins and can be stably stored over a long time while showing neither changes in appearance nor decrease in content.There are provided a stabilized albumin preparation produced by uniformly mixing a medium-chain fatty acid or a salt thereof and a sulfur-containing amino acid or a derivative thereof with an aqueous albumin solution (e.g., a buffer such as phosphate buffer which can be administered as pharmaceutical preparations, injection water, or a physiological saline) and dissolving them therein, and then processing the mixture solution into a formulation suitable for parenteral administration such as an intravenous fluid preparation or an injectable solution, and a stabilization method for an albumin preparation.